Previous 10 | Next 10 |
Research presented at the Annual Meeting of the Society of Biological Psychiatry and of the American Society of Clinical Psychopharmacology highlight fundamentally differentiated mechanism of action for PH94B These preclinical data demonstrate that intranasal radiolabelled...
VectorBuilder announced plans to build a $500 million gene delivery manufacturing and research campus in Guangzhou. Bayer announced China approval of Vitrakvi™ (larotrectinib), a precision medicine for adult and pediatric patients who have advanced solid tumors that harbor a Ne...
VistaGen Therapeutics (NASDAQ:VTGN) and AffaMed Therapeutics said they have completed regulatory preparations to begin a phase 3 trial of VistaGen’s nasal spray PH94B (AM005) for the acute treatment of anxiety in adults with social anxiety disorder (SAD), in the U.S. and China. Th...
Companies plan to initiate the global study of PH94B for the acute treatment of social anxiety disorder (SAD) in the second half of 2022 Trial designed to support commercialization of PH94B in China and other markets outside the U.S. VistaGen Therapeutics, Inc. (Nasd...
VistaGen (NASDAQ: VTGN) , a late clinical-stage, neuro-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced that its Chief Executive O...
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, neuro-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other centr...
Gainers: Orphazyme ORPH +22%. Y-mAbs Therapeutics YMAB +11%. Oscar Health (NYSE:OSCR) +9%. Theravance Biopharma TBPH +9%. VistaGen Therapeutics (NASDAQ:VTGN) +8%. Losers: ProQR Therapeutics PRQR -72%. Senseonics SENS -19%. PetVivo P...
VistaGen Therapeutics (NASDAQ: VTGN ), a company developing therapeutics to transform the treatment paradigm for patients suffering from anxiety, depression and other central nervous system disorders, has reported its third-quarter 2022 financial and business status. Highlights of the repor...
VistaGen Therapeutics, Inc. (VTGN) Q3 2022 Earnings Conference Call February 10, 2022 17:00 ET Company Participants Mark Flather - Vice President, Investor Relations Shawn Singh - Chief Executive Officer Jerry Dotson - Chief Financial Officer Mark Smith - Chief Medical Officer Conference Call...
VistaGen Therapeutics press release (NASDAQ:VTGN): Q3 GAAP EPS of -$0.05 beats by $0.02. Revenue of $0.36M (+16.1% Y/Y) beats by $0.11M. At December 31, 2021, the Company had cash and cash equivalents of approximately $83.7 million. For further details see: VistaGen Therapeutics GAAP EP...
News, Short Squeeze, Breakout and More Instantly...
VistaGen Therapeutics Inc. Company Name:
VTGN Stock Symbol:
NASDAQ Market:
VistaGen Therapeutics Inc. Website:
Vistagen Therapeutics (NASDAQ: VTGN ), a clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, has received multiple new patent...
Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global in...
Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has been recognized by Mental Health America (“MHA”) for its dedication to pr...